These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1799474)
1. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone. Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474 [TBL] [Abstract][Full Text] [Related]
2. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study. Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919 [TBL] [Abstract][Full Text] [Related]
3. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680 [TBL] [Abstract][Full Text] [Related]
4. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group. Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307 [No Abstract] [Full Text] [Related]
6. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799 [TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681 [TBL] [Abstract][Full Text] [Related]
8. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664 [TBL] [Abstract][Full Text] [Related]
9. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. Hiddemann W; Unterhalt M; Herrmann R; Wöltjen HH; Kreuser ED; Trümper L; Reuss-Borst M; Terhardt-Kasten E; Busch M; Neubauer A; Kaiser U; Hanrath RD; Middeke H; Helm G; Freund M; Stein H; Tiemann M; Parwaresch R J Clin Oncol; 1998 May; 16(5):1922-30. PubMed ID: 9586911 [TBL] [Abstract][Full Text] [Related]
10. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Enschede SH; Porter C; Venugopal P; Gregory SA Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187 [TBL] [Abstract][Full Text] [Related]
12. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423 [TBL] [Abstract][Full Text] [Related]
13. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy. Chisesi T Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma. Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972 [TBL] [Abstract][Full Text] [Related]
15. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698 [TBL] [Abstract][Full Text] [Related]
17. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385 [TBL] [Abstract][Full Text] [Related]
18. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Romaguera J; Rodriguez MA; Lee MS; Pate O; Sarris A; Younes A Ann Oncol; 1994; 5 Suppl 2():73-7. PubMed ID: 7515650 [TBL] [Abstract][Full Text] [Related]
19. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study . Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S; Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633 [TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302 [No Abstract] [Full Text] [Related] [Next] [New Search]